Innovators and generics, neither are wholly satisfied with the current Canadian system of intellectual property and related rights (IPRs). Ongoing trade negotiations between Canada and the European Union has fuelled the debate over effective IPR for innovative pharmaceutical products.
Read the full article, written by Steven Garland and Daphne Lainson of our Ottawa office, which appeared in the August 2012 issue of Intellectual Property Magazine.
Related Publications & Articles
-
Minister of Health announces new bilateral agreements with provinces for rare disease drugs
Canada’s first-ever National Strategy for Drugs for Rare Diseases includes up to $1.4 billion in funding for provinces and territories, to be negotiated through bilateral agreements.Read More -
Alexion awarded injunction against Amgen in SOLIRIS patent action; Court considers anticipation by incorporation by reference
The Federal Court has granted Alexion a declaration of infringement and an injunction preventing Amgen from manufacturing, using, and selling its proposed biosimilar eculizumab product, BEKEMV, in Can...Read More -
Update on biosimilars in Canada – June 2025
This article provides an update on developments in the biosimilar space in Canada—regulatory, approvals, pending submissions, litigation, and market access.Read More